RXST 📈 Rxsight - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US78349D1072
RXST: Light Adjustable Lenses, Light Delivery Devices
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. Web URL: https://www.rxsight.com
Additional Sources for RXST Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RXST Stock Overview
Market Cap in USD | 1,551m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Supplies |
IPO / Inception | 2021-07-30 |
RXST Stock Ratings
Growth 5y | 60.0% |
Fundamental | -30.0% |
Dividend | - |
Rel. Strength Industry | -335 |
Analysts | 4.5/5 |
Fair Price Momentum | 32.11 USD |
Fair Price DCF | - |
RXST Dividends
No Dividends PaidRXST Growth Ratios
Growth Correlation 3m | -77.4% |
Growth Correlation 12m | -22.1% |
Growth Correlation 5y | 87.2% |
CAGR 5y | 25.79% |
CAGR/Mean DD 5y | 1.37 |
Sharpe Ratio 12m | -0.10 |
Alpha | -43.80 |
Beta | 1.09 |
Volatility | 74.12% |
Current Volume | 468.7k |
Average Volume 20d | 836.6k |
What is the price of RXST stocks?
As of December 28, 2024, the stock is trading at USD 35.05 with a total of 468,673 shares traded.
Over the past week, the price has changed by -8.22%, over one month by -23.90%, over three months by -28.32% and over the past year by -11.27%.
As of December 28, 2024, the stock is trading at USD 35.05 with a total of 468,673 shares traded.
Over the past week, the price has changed by -8.22%, over one month by -23.90%, over three months by -28.32% and over the past year by -11.27%.
Is Rxsight a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Rxsight (NASDAQ:RXST) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -30.03 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RXST as of December 2024 is 32.11. This means that RXST is currently overvalued and has a potential downside of -8.39%.
Probably not. Based on ValueRay Fundamental Analyses, Rxsight (NASDAQ:RXST) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -30.03 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RXST as of December 2024 is 32.11. This means that RXST is currently overvalued and has a potential downside of -8.39%.
Is RXST a buy, sell or hold?
Rxsight has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy RXST.
Rxsight has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy RXST.
- Strong Buy: 6
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecast for RXST stock price target?
According to ValueRays Forecast Model, RXST Rxsight will be worth about 35.8 in December 2025. The stock is currently trading at 35.05. This means that the stock has a potential upside of +2.11%.
According to ValueRays Forecast Model, RXST Rxsight will be worth about 35.8 in December 2025. The stock is currently trading at 35.05. This means that the stock has a potential upside of +2.11%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 60.5 | 72.6% |
Analysts Target Price | 33.8 | -3.6% |
ValueRay Target Price | 35.8 | 2.1% |